Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections

Anaerobe

Volumn 9, Issue 2, 2003, Pages 75-81

  Stein, Gary E ^a   Goldstein, Ellie J C ^b,c,d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b R M ALDEN RESEARCH LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

Anaerobe; Bites; Levofloxacin; Sinusitis; Synergy

Indexed keywords

LEVOFLOXACIN;

BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BITE WOUND; BONE INFECTION; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SINUSITIS; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; WOUND INFECTION;

BACTEROIDES FRAGILIS;

EID: 0038721883     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1075-9964(03)00056-8     Document Type: Conference Paper

References (35)

1. North D.S., Fish D.N., Redington J.J. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy. 18:1998;915-935.
2. Wexler H.M., Molitoris E., Molitoris D., Finegold S.M. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob Agents Chemother. 42:1998;984-986.
3. Goldstein E.J.C., Nesbit C.A., Citron D.M. Comparative in vitro activities of azithromycin, Bay y3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother. 39:1995;1097-1100.
4. Goldstein E.J.C., Citron D.M., Warren Y., Tyrrell K., Merriam C.V. In vitro activity of gemifloxacin (SB265805) against anaerobes. Antimicrob Agents Chemother. 43:1999;2231-2235.
5. Alexander C.J., Goldstein E.J.C., Citron D.M., DeChermey A.H. Review of the comparative in vitro susceptibilities of lower female genital tract pathogens to older and newer fluoroquinolones. Anaerobe. 6:2000;313-323.
6. Talan D.A., Citron D.M., Abrahamian F.A., Moran G.J., Goldstein E.J.C. The Emergency Medicine Animal Bite Infection Study Group. The bacteriology and management of dog and cat bite wound infections presenting to Emergency Departments. N Engl J Med. 340:1999;85-92.
7. Goldstein E.J.C., Citron D.M., Gerardo S.H., Hudspeth M., Merriam C.V. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother. 41:1997;1193-1195.
8. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Fernandez H. In vitro activities of the Des-Fluoro (6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob Agents Chemother. 46:2002;866-870.
9. Goldstein E.J.C., Citron D.M., Merriam C.V., Tyrrell K., Warren Y. Activity of Gatifloxacin compared to five other quinolones vs. aerobic & anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother. 43:1999;1475-1479.
10. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J. Antimicrob Chemother. 48:2001;641-651.
11. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., Tyrrell K.L. Comparative in vitro activity of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother. 44:2000;2747-2751.
12. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y., Tyrrell K. Comparative in vitro activity of ABT-773 against aerobic and anaerobic pathogens isolated from skin & soft tissue animal & human bite wound infections. Antimicrob Agents Chemother. 44:2000;2525-2529.
13. Finegold S.M., Flynn M.J., Rose F.V., Joussimies-Sommer H., Jakielaszek C., McTeague M., Wexler H.M., Berkowitz E., Wynne B. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis. 35:2002;428-433.
14. Brook I. Anaerobic bacteria in upper respiratory tract and other head and neck infections. Ann Otol Rhinol Laryngol. 111(5Pt1):2002;430-440.
15. Goldstein E.J.C., Citron D.M., Merriam C.V. Comparative in vitro activities of amoxicillin-clavulante against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother. 43:1999;705-707.
16. Goldstein E.J.C., Conrads G., Citron D.M., Merriam C.V., Warren Y., Tyrrell K. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Diagn Microbiol Infect Dis. 42:2002;113-118.
17. Goldstein E.J.C., Conrads G., Citron D.M., Merriam C.V., Warren Y., Tyrrell K. Comparative in vitro activity of gemifloxacin against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Diagn Microbiol Infect Dis. 42:2002;113-118.
18. Goldstein E.J.C., Conrads G., Citron D.M., Merriam C.V., Warren Y., Tyrrell K.L. Comparative in vitro activity of ABT-773, a new ketolide, and other oral agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patient with sinusitis. Antimicrob Agents Chemother. 45:2001;2363-2367.
19. Ackermann G., Schaumann R., Pless B., Claros M.C., Goldstein E.J.C., Rodloff A.C. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 19:2000;228-232.
20. Appelbaum P.C. Quinolone activity against anaerobes. Drugs. 58(2Suppl 2):1999;60-64.
21. Goldstein E.J.C., Citron D.M., Nesbit C. Comparative activity of sparfloxacin, levofloxacin, and eight other oral agents against bacteria isolated from consecutive cases of diabetic foot infections. Diabetes Care. 19:1996;638-641.
22. Goldstein E.J.C., Citron D.M. Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction with metronidazole. Antimicrob Agents Chemother. 35:1991;2447-2449.
23. Credito K.L., Jacobs M.R., Appelbaum P.C. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn Microbiol Infect Dis. 38:2000;181-183.
24. Ross G.H., Wright D.H., Hovde L.B., Peterson M.L., Rotschafer J.C. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 45:2001;2136-2140.
25. Peterson M.L., Hovde L.B., Wright D.H., Brown G.H., Hoang A.D., Rotschafer J.C. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 46:2002;203-210.
26. Pendland S.L., Diaz-Linares M., Garey K.W., Woodward J.G., Ryu S., Danziger L.H. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother. 43:1999;2547-2549.
27. Spangler S.K., Jacobs M.R., Appelbaum P.C. Bactericidal activity of DU-6859a compared to activities of three quinolones, three β-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother. 41:1997;847-849.
28. Stein GE, Schooley SL, Tyrell KL, Citron DM, Goldstein EJC. Serum bactericidal activity of levofloxacin against anaerobic pathogens. In: Abstracts of the Sixth Biennial Congress of the Anaerobe Society of the Americas, 2002, Park City, UT [Abstract pII-17].
29. National Committee for Clinical Laboratory Standards. Methodology for the serum bactericidal test. National Committee for Clinical Laboratory Standards, Villanova, PA
30. Chow A.T., Fowler C., Williams R.R., Morgan N., Kaminski S., Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 45:2001;2122-2125.
31. Yamada Y., Mikamo H., Izumi K., Ito K., Tamaya T. Basic and clinical studies of levofloxacin in obstetrics and gynaecology. Drugs. 45(Suppl 3):1993;385.
32. Nicrodemo A.C., Robledo J.A., Jasovich A., Neto W. A multicentre, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract. 52:1998;69-74.
33. Graham D.R., Talan D.A., Nichols R.L., Lucasti C., Corrado M., Morgan N., Fowler C.L. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate for complicated skin and skin-structure infections. a randomized, open-label trial Clin Infect Dis. 35:2002;381-389.
34. Kahn JB, Wiesinger GA, Williams RR, Corrado M, Dornseif BE. Levaquin in the treatment of chronic osteomyelitis. In: Abstracts of the IDSA 36th Annual Meeting, 1998, Denver, CO. [Abstract 133].
35. Data on File. Ortho-McNeil Pharmaceutical.